Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

ViiV’s two-drug HIV combo backed by CHMP

The committee also backs two biosimilar medicines

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

Let’s change the conversation about cancer

The changing identity of cancer

José Baselga joins BMS’ board of directors

He will serve as a member of the science and technology committee

Bristol-Myers Squibb (BMS) building

BMS gets OK for monthly Opdivo dosing

Analysts predict the new dosing schedule could see the pharma giant win market share

Bristol-Myers Squibb (BMS) building

Yale Cancer Center joins BMS’ II-ON

Becomes the 16th institute to join the network

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo plus Yervoy aces phase III trial

The cancer drug combo met one of its primary endpoints in NSCLC patients

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy picks up another indication in Europe

The EC licenses the immuno-oncology treatment for children with skin cancer

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links